Ischemia Reperfusion Injury - Pipeline Review, H1 2015

Ischemia Reperfusion Injury - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Ischemia Reperfusion Injury - Pipeline Review, H1 2015’, provides an overview of the Ischemia Reperfusion Injury’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Ischemia Reperfusion Injury and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Ischemia Reperfusion Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Ischemia Reperfusion Injury pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Ischemia Reperfusion Injury Overview
Therapeutics Development
Pipeline Products for Ischemia Reperfusion Injury - Overview
Pipeline Products for Ischemia Reperfusion Injury - Comparative Analysis
Ischemia Reperfusion Injury - Therapeutics under Development by Companies
Ischemia Reperfusion Injury - Therapeutics under Investigation by Universities/Institutes
Ischemia Reperfusion Injury - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Ischemia Reperfusion Injury - Products under Development by Companies
Ischemia Reperfusion Injury - Products under Investigation by Universities/Institutes
Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development
Adienne Pharma & Biotech
Alligator Bioscience AB
Antipodean Pharmaceuticals, Inc.
BioLineRx, Ltd.
Biomedica Management Corporation
Bolder Biotechnology, Inc.
Catalyst Biosciences, Inc.
Curatis Pharma GmbH
Gilead Sciences, Inc.
Ischemix
LG Life Sciences, Ltd.
Lotus Pharmaceutical Co., Ltd.
Mercury Pharmaceuticals, Inc.
Omeros Corporation
Opsona Therapeutics Ltd.
Peptinnovate Limited
Pharming Group N.V.
PledPharma AB
Prolong Pharmaceuticals
Proteo, Inc.
Prothix BV
Trophos SA
Zealand Pharma A/S
Zyrnat Biotherapeutics SL
Ischemia Reperfusion Injury - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ADC-1004 - Drug Profile
AM/AMBP-1 - Drug Profile
ANV-6L15 - Drug Profile
APP-103 - Drug Profile
BBT-030 - Drug Profile
BBT-045 - Drug Profile
BL-7060 - Drug Profile
C1 esterase inhibitor (recombinant) - Drug Profile
CB-2782 - Drug Profile
CMX-2043 - Drug Profile
CRX-526 - Drug Profile
Curaglutide - Drug Profile
danegaptide - Drug Profile
Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury - Drug Profile
Drugs to Modulate NKT II Cells for Autoimmune, Gastrointestinal and Cardiovascular Disorders - Drug Profile
Elafin - Drug Profile
EP-80317 - Drug Profile
Ergidina - Drug Profile
GS-459679 - Drug Profile
KN-93 - Drug Profile
KR-62980 - Drug Profile
LSNTU-106 - Drug Profile
mangafodipir - Drug Profile
MFH-244 - Drug Profile
MG-53 - Drug Profile
mirococept - Drug Profile
MitoQ - Drug Profile
Monoclonal Antibody for Ischemia Reperfusion Injury - Drug Profile
Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury - Drug Profile
Monoclonal Antibody to Inhibit IL-16 for Ischemia Reperfusion Injury - Drug Profile
MTP-131 - Drug Profile
NBD Peptide - Drug Profile
NecX - Drug Profile
Neutrolide - Drug Profile
NOXD-21 - Drug Profile
Oligonucleotide for Oncology and Cardiovascular - Drug Profile
OMS-721 - Drug Profile
OPN-305 - Drug Profile
PAC-G31P - Drug Profile
Peptide to Activate AGTR1 for Cardiovascular, Metabolic Disorders, Immunology, Genito Urinary System And Sex Hormones - Drug Profile
PIN-201601 - Drug Profile
PRO-02 - Drug Profile
Protein for Ischemia/Reperfusion Injury - Drug Profile
R-190 - Drug Profile
Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia - Drug Profile
Recombinant Protein for Sepsis, Inflammatory bowel disease, Acute Kidney Injury, Acute radiation syndrome and Ischemic organ injury - Drug Profile
Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile
Recombinat Proten to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury - Drug Profile
Sanguinate - Drug Profile
Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile
Small Molecules for Ischemia Reperfusion Injury - Drug Profile
Small Molecules for Ischemia Reperfusion Injury - Drug Profile
Small Molecules for Ischemia Reperfusion Injury and Inflammation - Drug Profile
Small Molecules to Activate AMPK for Ischemia Reperfusion Injury - Drug Profile
Small Molecules to Activate SGK-1 for Ischemic Reperfusion Injury - Drug Profile
Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile
SMTP-7 - Drug Profile
Synthetic Peptides for Ischemia Reperfusion Injury - Drug Profile
Synthetic Peptides for Oncology, Immunology and Cardiovascular Disorders - Drug Profile
TRO-40303 - Drug Profile
UCF-101 - Drug Profile
UWA-TAT - Drug Profile
ZY-11 - Drug Profile
Ischemia Reperfusion Injury - Recent Pipeline Updates
Ischemia Reperfusion Injury - Dormant Projects
Ischemia Reperfusion Injury - Discontinued Products
Ischemia Reperfusion Injury - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Ischemia Reperfusion Injury, H1 2015
Number of Products under Development for Ischemia Reperfusion Injury - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Ischemia Reperfusion Injury - Pipeline by Adienne Pharma & Biotech, H1 2015
Ischemia Reperfusion Injury - Pipeline by Alligator Bioscience AB, H1 2015
Ischemia Reperfusion Injury - Pipeline by Antipodean Pharmaceuticals, Inc., H1 2015
Ischemia Reperfusion Injury - Pipeline by BioLineRx, Ltd., H1 2015
Ischemia Reperfusion Injury - Pipeline by Biomedica Management Corporation, H1 2015
Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology, Inc., H1 2015
Ischemia Reperfusion Injury - Pipeline by Catalyst Biosciences, Inc., H1 2015
Ischemia Reperfusion Injury - Pipeline by Curatis Pharma GmbH, H1 2015
Ischemia Reperfusion Injury - Pipeline by Gilead Sciences, Inc., H1 2015
Ischemia Reperfusion Injury - Pipeline by Ischemix, H1 2015
Ischemia Reperfusion Injury - Pipeline by LG Life Sciences, Ltd., H1 2015
Ischemia Reperfusion Injury - Pipeline by Lotus Pharmaceutical Co., Ltd., H1 2015
Ischemia Reperfusion Injury - Pipeline by Mercury Pharmaceuticals, Inc., H1 2015
Ischemia Reperfusion Injury - Pipeline by Omeros Corporation, H1 2015
Ischemia Reperfusion Injury - Pipeline by Opsona Therapeutics Ltd., H1 2015
Ischemia Reperfusion Injury - Pipeline by Peptinnovate Limited, H1 2015
Ischemia Reperfusion Injury - Pipeline by Pharming Group N.V., H1 2015
Ischemia Reperfusion Injury - Pipeline by PledPharma AB, H1 2015
Ischemia Reperfusion Injury - Pipeline by Prolong Pharmaceuticals, H1 2015
Ischemia Reperfusion Injury - Pipeline by Proteo, Inc., H1 2015
Ischemia Reperfusion Injury - Pipeline by Prothix BV, H1 2015
Ischemia Reperfusion Injury - Pipeline by Trophos SA, H1 2015
Ischemia Reperfusion Injury - Pipeline by Zealand Pharma A/S, H1 2015
Ischemia Reperfusion Injury - Pipeline by Zyrnat Biotherapeutics SL, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Ischemia Reperfusion Injury Therapeutics - Recent Pipeline Updates, H1 2015
Ischemia Reperfusion Injury - Dormant Projects, H1 2015
Ischemia Reperfusion Injury - Dormant Projects (Contd..1), H1 2015
Ischemia Reperfusion Injury - Dormant Projects (Contd..2), H1 2015
Ischemia Reperfusion Injury - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Ischemia Reperfusion Injury, H1 2015
Number of Products under Development for Ischemia Reperfusion Injury - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook